X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LEM-mR203 is the first mRNA vaccine candidate to which Lemonex's proprietary drug delivery platform technology, DegradaBALL (DegradaBALL-mRNA system), is applied, investigating for the treatment of Covid-19 infection.
Lead Product(s): LEM-mR203
Therapeutic Area: Infections and Infectious Diseases Product Name: LEM-mR203
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2023
Details:
LEM-mR203 is a safer and more efficient mRNA vaccine candidate by applying DegradaBALL® technology that can complement the limitations of LNP. It is being investigated as a booster shot for Covid-19.
Lead Product(s): LEM-mR203
Therapeutic Area: Infections and Infectious Diseases Product Name: LEM-mR203
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
LEM-S401 is a siRNA gene therapy drug that can treat and prevent hypertrophic scars, also claims to minimize the incidence of scars and the ability to remove pre-existing scars, increasing quality of life for patients.
Lead Product(s): LEM-S401
Therapeutic Area: Dermatology Product Name: LEM-S401
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
